Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils

[1]  A. B. Lyons,et al.  PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment , 2016, Front. Immunol..

[2]  A. B. Lyons,et al.  Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils , 2016, Biology Letters.

[3]  A. B. Lyons,et al.  Mitogen‐activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells , 2016, Immunology and cell biology.

[4]  S. Baldwin,et al.  Widespread transmission of independent cancer lineages within multiple bivalve species , 2016, Nature.

[5]  A. B. Lyons,et al.  A second transmissible cancer in Tasmanian devils , 2015, Proceedings of the National Academy of Sciences.

[6]  A. B. Lyons,et al.  Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil. , 2015, Developmental and comparative immunology.

[7]  S. Goff,et al.  Horizontal Transmission of Clonal Cancer Cells Causes Leukemia in Soft-Shell Clams , 2015, Cell.

[8]  Adriana Baz Morelli,et al.  The Combination of ISCOMATRIX Adjuvant and TLR Agonists Induces Regression of Established Solid Tumors In Vivo , 2015, The Journal of Immunology.

[9]  A. Papenfuss,et al.  Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors , 2014, Anatomical record.

[10]  Menna E. Jones,et al.  Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer , 2013, Proceedings of the National Academy of Sciences.

[11]  S. Koernig,et al.  ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. , 2012, Journal of medical microbiology.

[12]  Menna E. Jones,et al.  New Insights into the Role of MHC Diversity in Devil Facial Tumour Disease , 2012, PloS one.

[13]  Menna E. Jones,et al.  Antigen-presenting genes and genomic copy number variations in the Tasmanian devil MHC , 2012, BMC Genomics.

[14]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[15]  A. B. Lyons,et al.  Natural Killer Cell Mediated Cytotoxic Responses in the Tasmanian Devil , 2011, PloS one.

[16]  K. Belov,et al.  Allorecognition in the Tasmanian Devil (Sarcophilus harrisii), an Endangered Marsupial Species with Limited Genetic Diversity , 2011, PloS one.

[17]  L. Old,et al.  Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ , 2011, Cancer Immunology, Immunotherapy.

[18]  A. Papenfuss,et al.  Tumor-Specific Diagnostic Marker for Transmissible Facial Tumors of Tasmanian Devils , 2011, Veterinary pathology.

[19]  Manolis Kellis,et al.  The Tasmanian Devil Transcriptome Reveals Schwann Cell Origins of a Clonally Transmissible Cancer , 2009, Science.

[20]  M. Houghton,et al.  Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers , 2009, Human vaccines.

[21]  Shelly Lachish,et al.  The impact of disease on the survival and population growth rate of the Tasmanian devil. , 2007, The Journal of animal ecology.

[22]  A. O'hara,et al.  The Immunohistochemical Characterization of Devil Facial Tumor Disease (DFTD) in the Tasmanian Devil (Sarcophilus harrisii) , 2006, Veterinary pathology.

[23]  Robin A. Weiss,et al.  Clonal Origin and Evolution of a Transmissible Cancer , 2006, Cell.

[24]  Clare E. Hawkins,et al.  Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii , 2006 .

[25]  Edgar Schmitt,et al.  Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. , 2006, Blood.

[26]  A. Pearse,et al.  Allograft theory: Transmission of devil facial-tumour disease , 2006, Nature.

[27]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[28]  James M. Murphy,et al.  In vitro JAK kinase activity and inhibition assays. , 2013, Methods in molecular biology.

[29]  J. Bergfeld,et al.  Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). , 2008, Developmental and comparative immunology.

[30]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .